KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EBITDA (2016 - 2025)

Historic EBITDA for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $853.1 million.

  • Regeneron Pharmaceuticals' EBITDA rose 41.2% to $853.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.6 billion, marking a year-over-year increase of 233.41%. This contributed to the annual value of $4.6 billion for FY2025, which is 233.41% up from last year.
  • Regeneron Pharmaceuticals' EBITDA amounted to $853.1 million in Q4 2025, which was up 41.2% from $1.5 billion recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' EBITDA registered a high of $3.1 billion during Q2 2021, and its lowest value of $725.7 million during Q1 2024.
  • Its 5-year average for EBITDA is $1.3 billion, with a median of $1.2 billion in 2021.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' EBITDA skyrocketed by 22895.21% in 2021 and then crashed by 7423.19% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' EBITDA (Quarter) stood at $2.2 billion in 2021, then plummeted by 43.77% to $1.2 billion in 2022, then grew by 1.79% to $1.3 billion in 2023, then crashed by 32.33% to $849.6 million in 2024, then rose by 0.41% to $853.1 million in 2025.
  • Its EBITDA was $853.1 million in Q4 2025, compared to $1.5 billion in Q3 2025 and $1.4 billion in Q2 2025.